Some studies have shown that patients with high levels of FOXP3+ TILs have poor chemosensitivity and worse prognosis, while others reported that breast cancer patients with high levels of FOXP3+ T cells had better outcomes [67, 68]. This evidence concerns the gene FOXP3 and breast carcinoma.